141 related articles for article (PubMed ID: 36735625)
1. Niclosamide is a potential candidate for the treatment of chemo-resistant osteosarcoma.
Huang X; Wang W; Li Y
Genet Mol Biol; 2023; 46(1):e20220136. PubMed ID: 36735625
[TBL] [Abstract][Full Text] [Related]
2. The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma Cells by Targeting Multiple Signal Pathways.
Liao Z; Nan G; Yan Z; Zeng L; Deng Y; Ye J; Zhang Z; Qiao M; Li R; Denduluri S; Wang J; Wei Q; Geng N; Zhao L; Lu S; Wang X; Zhou G; Luu HH; Haydon RC; He TC; Wang Z
Curr Cancer Drug Targets; 2015; 15(8):726-38. PubMed ID: 26118906
[TBL] [Abstract][Full Text] [Related]
3. Targeting Wnt/β-catenin by anthelmintic drug niclosamide overcomes paclitaxel resistance in esophageal cancer.
Wei W; Liu H; Yuan J; Yao Y
Fundam Clin Pharmacol; 2021 Feb; 35(1):165-173. PubMed ID: 32579788
[TBL] [Abstract][Full Text] [Related]
4. Niclosamide and Pyrvinium Are Both Potential Therapeutics for Osteosarcoma, Inhibiting Wnt-Axin2-Snail Cascade.
Yi Y; Woo YM; Hwang KH; Kim HS; Lee SH
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572856
[TBL] [Abstract][Full Text] [Related]
5. Niclosamide Suppresses Migration and Invasion of Human Osteosarcoma Cells by Repressing TGFBI Expression via the ERK Signaling Pathway.
Yeh LT; Lin CW; Lu KH; Hsieh YH; Yeh CB; Yang SF; Yang JS
Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008910
[TBL] [Abstract][Full Text] [Related]
6. Niclosamide suppresses renal cell carcinoma by inhibiting Wnt/β-catenin and inducing mitochondrial dysfunctions.
Zhao J; He Q; Gong Z; Chen S; Cui L
Springerplus; 2016; 5(1):1436. PubMed ID: 27652012
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Evaluation and Mitigation of Niclosamide's Liabilities as a COVID-19 Treatment.
Wotring JW; McCarty SM; Shafiq K; Zhang CJ; Nguyen T; Meyer SR; Fursmidt R; Mirabelli C; Clasby MC; Wobus CE; O'Meara MJ; Sexton JZ
bioRxiv; 2022 Jul; ():. PubMed ID: 35860224
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel triazole inhibitors of Wnt/β-catenin signaling based on the Niclosamide chemotype.
Mook RA; Wang J; Ren XR; Piao H; Lyerly HK; Chen W
Bioorg Med Chem Lett; 2019 Jan; 29(2):317-321. PubMed ID: 30551901
[TBL] [Abstract][Full Text] [Related]
9. Identification of DK419, a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth.
Wang J; Mook RA; Ren XR; Zhang Q; Jing G; Lu M; Spasojevic I; Lyerly HK; Hsu D; Chen W
Bioorg Med Chem; 2018 Nov; 26(20):5435-5442. PubMed ID: 30274939
[TBL] [Abstract][Full Text] [Related]
10. The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression.
Guo Y; Zhu H; Xiao Y; Guo H; Lin M; Yuan Z; Yang X; Huang Y; Zhang Q; Bai Y
Cell Death Dis; 2022 Feb; 13(2):112. PubMed ID: 35115509
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Wnt/β-catenin by anthelmintic drug niclosamide effectively targets growth, survival, and angiogenesis of retinoblastoma.
Li Z; Li Q; Wang G; Huang Y; Mao X; Zhang Y; Wang X
Am J Transl Res; 2017; 9(8):3776-3786. PubMed ID: 28861168
[TBL] [Abstract][Full Text] [Related]
12. In Vitro Evaluation and Mitigation of Niclosamide's Liabilities as a COVID-19 Treatment.
Wotring JW; McCarty SM; Shafiq K; Zhang CJ; Nguyen T; Meyer SR; Fursmidt R; Mirabelli C; Clasby MC; Wobus CE; O'Meara MJ; Sexton JZ
Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016172
[TBL] [Abstract][Full Text] [Related]
13. Niclosamide, a Drug with Many (Re)purposes.
Kadri H; Lambourne OA; Mehellou Y
ChemMedChem; 2018 Jun; 13(11):1088-1091. PubMed ID: 29603892
[TBL] [Abstract][Full Text] [Related]
14. Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway.
Liu Z; Li Y; Lv C; Wang L; Song H
Biochem Biophys Res Commun; 2016 Sep; 478(2):893-9. PubMed ID: 27520370
[TBL] [Abstract][Full Text] [Related]
15. Niclosamide inhibits the proliferation of human osteosarcoma cell lines by inducing apoptosis and cell cycle arrest.
Li Z; Yu Y; Sun S; Qi B; Wang W; Yu A
Oncol Rep; 2015 Apr; 33(4):1763-8. PubMed ID: 25634333
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Testing of a Novel Niclosamide Stearate Prodrug Therapeutic (NSPT) Shows Efficacy Against Osteosarcoma.
Reddy GB; Kerr DL; Spasojevic I; Tovmasyan A; Hsu DS; Brigman BE; Somarelli JA; Needham D; Eward WC
Mol Cancer Ther; 2020 Jul; 19(7):1448-1461. PubMed ID: 32371588
[TBL] [Abstract][Full Text] [Related]
17. Niclosamide: A career builder.
Needham D
J Control Release; 2024 May; 369():786-856. PubMed ID: 37544514
[TBL] [Abstract][Full Text] [Related]
18. Niclosamide-induced Wnt signaling inhibition in colorectal cancer is mediated by autophagy.
Wang J; Ren XR; Piao H; Zhao S; Osada T; Premont RT; Mook RA; Morse MA; Lyerly HK; Chen W
Biochem J; 2019 Feb; 476(3):535-546. PubMed ID: 30635359
[TBL] [Abstract][Full Text] [Related]
19. The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical and noncanonical Wnt signaling pathway.
Monin MB; Krause P; Stelling R; Bocuk D; Niebert S; Klemm F; Pukrop T; Koenig S
J Surg Res; 2016 Jun; 203(1):193-205. PubMed ID: 27338550
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-1246 by Targeting AXIN2 and GSK-3β Overcomes Drug Resistance and Induces Apoptosis in Chemo-resistant Leukemia Cells.
Xie B; Li L; Zhang Z; Zhao L; Cheng J; Zhou C; Cheng J; Yan J; Chen J; Yi J; Wang B; Jin S; Wei H
J Cancer; 2021; 12(14):4196-4208. PubMed ID: 34093820
[No Abstract] [Full Text] [Related]
[Next] [New Search]
